139 related articles for article (PubMed ID: 22847535)
41. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
42. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.
Ciravolo V; Huber V; Ghedini GC; Venturelli E; Bianchi F; Campiglio M; Morelli D; Villa A; Della Mina P; Menard S; Filipazzi P; Rivoltini L; Tagliabue E; Pupa SM
J Cell Physiol; 2012 Feb; 227(2):658-67. PubMed ID: 21465472
[TBL] [Abstract][Full Text] [Related]
43. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy.
Tonini G; Vincenzi B; Santini D; Avvisati G; La Cesa A; Baldi A
J Clin Oncol; 2003 Jun; 21(11):2215-6. PubMed ID: 12775749
[No Abstract] [Full Text] [Related]
44. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
Brufsky A
Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
[TBL] [Abstract][Full Text] [Related]
45. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.
Gennari R; Menard S; Fagnoni F; Ponchio L; Scelsi M; Tagliabue E; Castiglioni F; Villani L; Magalotti C; Gibelli N; Oliviero B; Ballardini B; Da Prada G; Zambelli A; Costa A
Clin Cancer Res; 2004 Sep; 10(17):5650-5. PubMed ID: 15355889
[TBL] [Abstract][Full Text] [Related]
46. Trastuzumab administration associated with change in HER2 status.
Dawood S; Resetkova E; Gonzalez-Angulo AM
Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
[TBL] [Abstract][Full Text] [Related]
47. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
48. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
49. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
50. What is the mechanism of progression with trastuzumab treatment--escape or resistance?
Sendur MA; Aksoy S; Özdemir NY; Zengin N; Altundağ K
Asian Pac J Cancer Prev; 2012; 13(11):5915-6. PubMed ID: 23317282
[TBL] [Abstract][Full Text] [Related]
51. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
53. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Huober J; Fasching PA; Barsoum M; Petruzelka L; Wallwiener D; Thomssen C; Reimer T; Paepke S; Azim HA; Ragosch V; Kubista E; Baumgärtner AK; Beckmann MW; May C; Nimmrich I; Harbeck N
Breast; 2012 Feb; 21(1):27-33. PubMed ID: 21862331
[TBL] [Abstract][Full Text] [Related]
54. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
55. Breakthrough in breast cancer treatment. "Smart bullet" T-DM1 delivers a payload to cancer cells and avoids healthy ones.
Duke Med Health News; 2012 Aug; 18(8):3. PubMed ID: 23029673
[No Abstract] [Full Text] [Related]
56. Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Géraud A; Xu HP; Beuzeboc P; Kirova YM
Cancer Radiother; 2016 Jun; 20(4):312-3. PubMed ID: 27342941
[No Abstract] [Full Text] [Related]
57. [10 years of testing of the HER2 status in breast cancer in Russia].
Frank GA; Andreeva IuIu; Vinogradov IIu; Glatko SB; Gorelik MZ; Zavalishina LE; Leenman EE; Matsionis AE; Petrov SV; Sazonov SV
Arkh Patol; 2012; 74(5):3-6. PubMed ID: 23342651
[TBL] [Abstract][Full Text] [Related]
58. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Martens J; Venuturumilli P; Corbets L; Bestul D
Acta Oncol; 2013 Jan; 52(1):175-8. PubMed ID: 22655969
[No Abstract] [Full Text] [Related]
59. Response of metastatic breast cancer to trastuzumab?
Barnes DM; Miles DW
Lancet; 2000 Jan; 355(9199):160-1. PubMed ID: 10675110
[No Abstract] [Full Text] [Related]
60. Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?
Livingston RB; Esteva FJ
Oncologist; 2001; 6(4):315-6. PubMed ID: 11524548
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]